Shilpa Medicare Limited has published a postal ballot notice seeking shareholder approval for shifting its registered office from Karnataka to Maharashtra. The company’s board approved the proposal on May 22, 2026. The resolution seeks approval for the inter-state relocation and the alteration of the situation clause of the Memorandum of Association.

The proposed relocation involves moving the registered office from Raichur, Karnataka, to Office No. 1, “A” Wing, Ground Floor, Trade Star Building, J.B. Nagar, Andheri – Kurla Road, Andheri (East), Mumbai -400059, Maharashtra. The company stated that the shift is driven by business and administrative considerations, citing better access to financial institutions, regulatory authorities, and stakeholders in Mumbai.

Financial Results

Alongside the postal ballot process, the company announced its standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. For the standalone results, total income from operations for the year ended March 31, 2026, stood at Rs. 59,703 lakh, compared to Rs. 47,741 lakh in the previous year. The net profit after tax for the year was Rs. 13,297 lakh, up from Rs. 6,789 lakh in the previous year. The Board has recommended a final dividend of Rs. 0.60 per equity share for the financial year 2025-26.

Postal Ballot and E-Voting Details

In compliance with SEBI (LODR) Regulations, the company has restricted the voting process to remote e-voting only. Physical postal ballot forms will not be dispatched. The notice was published in Business Line and Saddi Moola newspapers on May 23, 2026. The notice and e-voting instructions have been sent electronically to members whose email addresses are registered with the Registrar and Share Transfer Agent, KFin Technologies Limited, or depositories as of the cut-off date of May 15, 2026.

Resolution and Scrutiny

The special resolution requires approval for the inter-state shift. Mr. Santosh Kumar Gunemoni has been appointed as the Scrutinizer. The results of the e-voting will be announced on or before June 24, 2026, and will be displayed on the company’s website and stock exchange platforms. Shareholders holding shares in physical or electronic form as on the cut-off date are eligible to vote.

Shilpa Medicare has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for the global Phase 3 plan for its Albumin product, marking a key regulatory milestone in the company's biopharmaceutical development journey.

CDSCO Approval for Global Phase 3 Plan

The CDSCO approval covers the global Phase 3 clinical plan for Albumin, enabling Shilpa Medicare to advance the programme towards international regulatory submissions. This clearance from India's apex drug regulatory authority represents a critical step in the clinical development pathway for the product.

EMA IMPD Submission Targeted in H1 FY27

Following the CDSCO approval, Shilpa Medicare has set its sights on submitting an Investigational Medicinal Product Dossier (IMPD) to the European Medicines Agency (EMA). The company is aiming to complete this submission in the first half of FY27, signalling its intent to pursue regulatory engagement in the European market for the Albumin programme.

Strategic Significance

The dual regulatory development — domestic approval from CDSCO and the planned IMPD submission to EMA — underscores Shilpa Medicare's focus on building a global clinical and regulatory footprint for its Albumin product. The IMPD is a mandatory dossier required by the EMA before initiating clinical trials within the European Union, making its timely submission a pivotal milestone in the product's international development trajectory.